|
|
 |
|
Viewing report
|
|
|
|
Metastatic Melanoma: Pipeline Assessment and Market Potential Through 2017
MP Advisors, Oct 2011, Pages: 65
Metastatic Melanoma therapy will witness a complete paradigm shift in the way the disease is treated as newer therapies with different mechanisms reach the market. The recent approval of BMY’s Yervoy (Ipilimumab) and Zelboraf (Vemurafenib) has come as good news for the metastatic melanoma patients and is just the beginning. The pipeline in metastatic melanoma is much crowded and there are many more exciting compounds on the anvil. Nab-paclitaxel, Avastin, Oncovex, Allovectin, BRAF and MEK inhibitors, C-Kit inhibitors, and several vaccines are being explored. These newer drugs have shown promising data and offer promise for an improved treatment options for the metastatic melanoma patients of the future.
Broadly there are five new classes of therapies that are expected to improve outcomes in patients with metastatic melanoma.
- Targeted Chemotherapy
- Anti-angiogenesis Therapy
- Targeted Immunotherapy
- Targeted MAP Kinase Therapy
- Vaccines
As the newer therapies have their own pros and cons to maximize the benefit for patients, clinical trials are also ongoing which are exploring the benefits of combination of these newer therapies when administered either concomitantly or sequentially. The future treatment paradigm in melanoma is going to be a real art of sequencing and combinations. On one hand you have a drug like Yeryoy, which does not have a great response rate, but promises durability of response for those who respond well, while on the other hand are BRAF inhibitors, which offer a dramatic response rate but lacks durability.
All in all, we will witness a flurry of newer therapies in the market over the next few years and physicians are likely to tailor the use of these newer therapies to suit the needs of an individual. The melanoma market which is currently worth about $500m will expand to become a $4b market by 2015.
This report analyses the merits and demerits of individual pipeline molecules in greater details along with sales estimate through 2017 for the important molecules across the world.
|
|
|
|
